Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 3/12/2025 | $175.00 → $170.00 | Sell | Guggenheim | |
| 3/10/2025 | $259.00 → $225.00 | Sell | UBS | |
| 3/7/2025 | $180.00 → $388.00 | Hold → Buy | TD Cowen | |
| 2/28/2025 | Mkt Perform | William Blair | ||
| 2/27/2025 | Buy → Hold | Summit Insights | ||
| 2/12/2025 | $475.00 | Buy | The Benchmark Company | |
| 1/30/2025 | $820.00 | Hold → Buy | The Benchmark Company | |
| 1/23/2025 | $660.00 → $710.00 | Buy | BofA Securities |
4 - Meta Platforms, Inc. (0001326801) (Issuer)
4 - Meta Platforms, Inc. (0001326801) (Issuer)
4 - Tesla, Inc. (0001318605) (Issuer)
4 - Aditxt, Inc. (0001726711) (Issuer)
4/A - NeuroBo Pharmaceuticals, Inc. (0001638287) (Issuer)
4 - NeuroBo Pharmaceuticals, Inc. (0001638287) (Issuer)
Guggenheim reiterated coverage of Tesla with a rating of Sell and set a new price target of $170.00 from $175.00 previously
UBS reiterated coverage of Tesla with a rating of Sell and set a new price target of $225.00 from $259.00 previously
TD Cowen upgraded Tesla from Hold to Buy and set a new price target of $388.00 from $180.00 previously
Ms. Lawver, former Chief Commercial Officer of Dexcom and Global Vice President at Johnson & Johnson responsible for billion-dollar Immunology and Cardiovascular & Metabolism Portfolios over her 20-year career Mr. Durso led biopharmaceutical company focused on liver disease as former CEO of Intercept Pharmaceuticals, previously oversaw multiple blockbuster franchises including cardiovascular and diabetes during 22-year tenure at Sanofi GAITHERSBURG, Md., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the expansion of its Board of Directors with the appointments of Teri Lawver and Jerry Durso. "We are thrilled
USA News Group News Commentary Issued on behalf of Scope Technologies Corp. VANCOUVER, BC , Jan. 31, 2025 /PRNewswire/ -- USA News Group News Commentary – The market is witnessing another tech revolution so far in 2025, kicking off the Trump presidency with the massive $500-billion Stargate AI project, which sent the S&P 500 to a new high. In the past two weeks, the tech industry has witnessed significant advancements in both artificial intelligence (AI) and quantum computing, signaling a transformative era for various sectors. Notably, quantum computing stocks have captured investors' attention, competing with AI stocks. Despite a recent roller coaster in the stocks of quantum computing com
MENLO PARK, Calif., Jan. 6, 2025 /PRNewswire/ -- Meta today announced that Dana White, John Elkann and Charlie Songhurst have been elected to the company's board of directors. Mark Zuckerberg, Founder and CEO of Meta, said, "Dana, John and Charlie will add a depth of expertise and perspective that will help us tackle the massive opportunities ahead with AI, wearables and the future of human connection." "I've never been interested in joining a board of directors until I got the offer to join Meta's board. I am a huge believer that social media and AI are the future," said Dana
SANTA CLARA, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- NVIDIA today announced ahead of the Game Developers Conference (GDC) groundbreaking enhancements to NVIDIA RTX™ neural rendering technologies. NVIDIA has partnered with Microsoft to bring neural shading support to the Microsoft DirectX preview in April, giving developers access to AI Tensor Cores in NVIDIA GeForce RTX™ GPUs to accelerate neural networks from within a game's graphics pipeline. Neural shading represents a revolution in graphics programming, combining AI with traditional rendering to dramatically boost frame rates, enhance image quality and reduce system resource usage. "Microsoft is adding cooperative vector support
Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, announced today that it will effect a 1-for-250 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on March 17, 2025, the Company's common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company's stockholders at the special meeting held on February 28, 2025, with the final ratio determined by the Company's board of directors. As a result of the reverse stock split, the CUSIP number for the Company's common stock will
Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today provided an update on its subsidiary, Adimune, Inc., ("Adimune") and its progress in advancing ADI-100, an investigational product candidate to be studied in patients with Psoriasis, Type I Diabetes (T1D) and Stiff Person Syndrome. Adimune's mission is to address the root causes of autoimmune diseases. By harnessing the body's natural ability to restore and maintain immune tolerance, Adimune strives to deliver innovative solutions that improve lives without the risks of immunosuppression. As a subsidiary of Aditxt, Adimune continues to advance
8-K - Altimmune, Inc. (0001326190) (Filer)
8-K - Aditxt, Inc. (0001726711) (Filer)
144 - Tesla, Inc. (0001318605) (Subject)
SC 13G - NeuroBo Pharmaceuticals, Inc. (0001638287) (Subject)
SC 13G/A - Altimmune, Inc. (0001326190) (Subject)
SC 13G/A - NVIDIA CORP (0001045810) (Subject)
New York, New York, March 03, 2025 (GLOBE NEWSWIRE) -- YieldBOOST is an innovative strategy that aims to combine high income potential by selling options on leveraged ETFs which generally command a higher premium than options on stocks, while focusing on NAV preservation by writing options which have a lower chance of being exercised ("out of the money" options). GraniteShares believes that this holistic approach is an improvement over existing option income strategies mainly known as "covered call" strategies. The main problem with covered call strategies is that they prioritize income or yield over total return. With a covered call, the options seller typically sells "at the money" whic
Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 2025 Investigational New Drug (IND) applications in two additional indications have received FDA clearance, with Phase 2 trials to commence mid-2025 Company to hold virtual R&D Day on March 13, 2025. Program will include KOL presentations on pemvidutide development in obesity, MASH and additional indications Two pharmaceutical industry veterans added to Company Board of Directors Cash, cash equivalents and short-term investments of $131.9 million on December 31, 2024 Webcast to be held today, February 27, 2025, at 8:30 a.m. ET GAITHERSBURG, Md., Feb.
Record quarterly revenue of $39.3 billion, up 12% from Q3 and up 78% from a year agoRecord quarterly Data Center revenue of $35.6 billion, up 16% from Q3 and up 93% from a year agoRecord full-year revenue of $130.5 billion, up 114% SANTA CLARA, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- NVIDIA (NASDAQ:NVDA) today reported revenue for the fourth quarter ended January 26, 2025, of $39.3 billion, up 12% from the previous quarter and up 78% from a year ago. For the quarter, GAAP earnings per diluted share was $0.89, up 14% from the previous quarter and up 82% from a year ago. Non-GAAP earnings per diluted share was $0.89, up 10% from the previous quarter and up 71% from a year ago. For fisca